SENORX INC
			Symbol			SENO

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

SenoRx Announces Revised Court Schedule in Pending Hologic v. SenoRx Litigation

2009-10-09 16:31 ET - News Release

IRVINE, Calif., Oct. 9, 2009 (GLOBE NEWSWIRE) -- SenoRx, Inc. (Nasdaq:SENO) today announced that the United States District Court for the Northern District of California has issued a revised court schedule for the pending patent litigation matter before the Court between Hologic and SenoRx.

The revised schedule set forth by the Court is:

 Pre-Trial Conference:  November 2, 2009
 Trial Start Date:  December 1, 2009
 Trial End Date:  December 17, 2009

Previously, the Court had set the trial start date for October 13, 2009.

About SenoRx

SenoRx (Nasdaq:SENO) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor(R) vacuum-assisted breast biopsy system and Contura(TM) MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. SenoRx's field sales organization serves over 2,000 breast diagnostic and treatment centers in the United States and Canada. In addition, SenoRx sells several of its products through distribution partners in more than 30 countries outside the U.S. and Canada. The company's line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is developing additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information, visit the company's website at www.senorx.com.

The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try, click here for a free 30 day trial subscription.